Shanghai Shyndec Pharmaceutical (600420.SH): Its controlling subsidiary Sinopharm ChuanKang has passed the drug GMP compliance inspection.

Shanghai Shyndec Pharmaceutical (600420.SH) announced that recently, its controlling subsidiary Sinopharm Group ChuanKang Pharmaceutical Co., Ltd. (referred to as Sinopharm ChuanKang) received the "Drug GMP Compliance Inspection Notification Letter" issued by the Sichuan Provincial Medical Products Administration. The workshop and production line involved in this GMP compliance inspection, namely the Fine Drying and Packaging 2 (API (Tacrolimus) production line), were newly put into use after production line renovation. The product currently produced is API (Tacrolimus), with a designed capacity of 100 kg/year. The API (Tacrolimus) production line of Sinopharm ChuanKang passed the drug GMP compliance inspection after upgrade and renovation, indicating that the production line and production process comply with the requirements of the "Good Manufacturing Practice for Drugs (2010 Revision)". This is conducive to the company expanding the production capacity scale of APIs in the immunosuppressant segment, promoting the integrated development of the API and formulation industry chain, and better meeting the market demand for related drugs. The above matters will not have a significant impact on the company's current operating performance.